Trial reportFrontiers in immunology2022
Repeat controlled human malaria infection of healthy UK adults with blood-stage
Trial report in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/IIa Clinical Trial to Assess the Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Falciparum Malaria Vaccine Candidate RH5.1/AS01
A Clinical Study to Assess the Safety of Primary, Secondary and Tertiary Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection of Healthy Malaria-naïve UK Adults, and to Characterise Parasite Growth Dynamics
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Diagnosis of Plasmodium falciparum malaria at very low parasitaemias using a commercially available LAMP assay and RDT.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2025Article
- Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection.Nature communications · 2025Article
- Plasmodium falciparum infection induces T cell tolerance that is associated with decreased disease severity upon re-infection.The Journal of experimental medicine · 2025Article
- Clone tracking through repeated malaria identifies high-fidelity memory CD4 T cell responses.Science immunology · 2025Article
- Clinical challenges and technological breakthroughs in helminthic therapy for diabetes.Frontiers in immunology · 2025Review
- Controlled human malaria infection studies: insights into recent advances and key immunological and ethical implementation lessons.Frontiers in immunology · 2025Review
- The impact of Plasmodium-driven immunoregulatory networks on immunity to malaria.Nature reviews. Immunology · 2024Review
- Repeat controlled human Plasmodium falciparum infections delay bloodstream patency and reduce symptoms.Nature communications · 2024Article
- Defining the next generation of severe malaria treatment: a target product profile.Malaria journal · 2024Review
- A systematic analysis of the human immune response to Plasmodium vivax.The Journal of clinical investigation · 2023Article
- The Dantu blood group prevents parasite growtheLife · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In endemic settings it is known that natural malaria immunity is gradually acquired following repeated exposures. Here we sought to assess whether similar acquisition of blood-stage malaria immunity would occur following repeated parasite exposure by controlled human malaria infection (CHMI). We report the findings of repeat homologous blood-stage Clinical Trial Registration: ClinicalTrials.gov, identifier NCT03906474, NCT02927145.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.